ETON vs INDV
ETON: Eton Pharmaceuticals develops and commercializes rare disease treatments, with a portfolio of ten marketed products and four late-stage candidates targeting ultra-rare genetic and metabolic disorders. INDV: Indivior is a specialty pharmaceutical company dedicated to developing and marketing treatments for substance use disorders and mental health conditions, anchored by its flagship injectable product, SUBLOCADE.
Side-by-side fundamentals
| Metric | ETON | INDV | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $43.58 | $40.45 | |
| Market cap as of 2026-07-23 | $1.2B | $4.9B | |
| P/E as of 2026-07-23 | n/a | 19.65 | |
| PEG as of 2026-07-23 | n/a | 0.83 | |
| Net margin as of 2026-07-23 | -1.7% | +19.4% | INDV higher |
| Gross margin as of 2026-07-23 | +54.8% | +81.3% | INDV higher |
| Operating margin as of 2026-07-23 | +2.4% | +24.4% | INDV higher |
| ROE as of 2026-07-23 | -5.7% | +159.1% | INDV higher |
| ROA as of 2026-07-23 | -1.5% | +19.1% | INDV higher |
| Debt / equity as of 2026-07-23 | 1.00 | 27.90 | ETON lower |
| Revenue growth (YoY) as of 2026-07-23 | +79.9% | +10.3% | ETON higher |
| Revenue CAGR (3y) SEC XBRL | +55.5% | +11.2% | ETON higher |
| Beta as of 2026-07-23 | 0.89 | 0.53 | |
| 1-year return as of 2026-07-22 close | +200.0% | +150.0% | ETON higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.